UP-02.172 The Appropriateness of Active Surveillance and the Impact of Prostate Cancer Gene 3 (PCA3) in Low Risk Prostate Cancer: An Analysis of Expert Opinion

Mark Speakman(Taunton & Somerset NHS Foundation Trust), Alessandro Volpe(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paolo Gontero(Fondazione Ricerca Molinette), Filip Ameye(Universitair Ziekenhuis Leuven), Philippe Perrin(Développement, Adaptation et Handicap), Herman Stoevelaar(Barnes-Jewish Hospital), Alexander Haese(Universität Hamburg), Paul J.M. Kil(Andros Clinica Day Surgery), J Schröder(Praxis für Hämatologie und Onkologie), Theo de Reijke(Amsterdam UMC Location University of Amsterdam), A. De La Taille, Mesut Remzi(Landesklinikum Korneuburg)
Urology
September 1, 2011
10.1016/j.urology.2011.07.990
Cited by 0

Related Papers

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
|European Urology|2015|639
Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy
|European Urology|2015|578
Laparoscopic versus Open Partial Nephrectomy: Analysis of the Current Literature
|European Urology|2008|221
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†
|European Urology|2019|194
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
|Annals of Oncology|2019|183